The company has not filed an annual or quarterly report since its FY2022 10-K, filed Mar 2, 2023. Its latest SEC filing is a SC 13D/A from Jun 15, 2023.
10-K for FY2022, filed Mar 2, 2023
The sections below describe the company as of the FY2022 annual report.
Sells instruments, chip consumables and software that analyze proteins in individual cells and bulk samples for biopharmaceutical companies and academic and research institutions.
10-K for FY2022, filed Mar 2, 2023IsoPlexis is empowering labs to leverage the cells and proteome changing the course of human health. Our systems assess cell behavior…View ↗
Our platform is an end-to-end solution comprised of our proprietary IsoLight and IsoSpark instruments, IsoCode and CodePlex chip…View ↗
As of December 31, 2022, we have placed 286 systems globally, including at each of the top 15 global biopharmaceutical companies by revenue…View ↗
Customers buy instruments and consumables, with payment typically due within 30 days of shipment. They pay for immune-response analysis when the data is made available, while extended service warranties are paid over their contract term.
10-K for FY2022, filed Mar 2, 2023
$16.8M
10-K for FY2022, filed Mar 2, 2023
$16.8M ↗
Biopharmaceutical companies and academic and research institutions buy the company’s products and services. It sells directly in North America and specific European regions, and through distributors across Europe, North America, the Middle East and Asia-Pacific.
10-K for FY2022, filed Mar 2, 2023As of December 31, 2022, we have placed 286 systems globally, including at each of the top 15 global biopharmaceutical companies by revenue…View ↗
Our revenue to date has been driven primarily by sales of our instruments and chip consumables. Revenue for the years ended December 31…View ↗
Our products are currently marketed (and we currently intend to continue to market them) as research use only (“RUO”) and we sell them to…View ↗
No. It lost $106M in FY2022.
10-K for FY2022, filed Mar 2, 2023
−$101.2MView ↗
10-K for FY2022, filed Mar 2, 2023
−$106MView ↗
10-K for FY2022, filed Mar 2, 2023
−$104MView ↗
8-K, filed Mar 22, 2023
As described above, at the Effective Time, and in accordance with the Merger Agreement, (i) Berkeley Lights completed its previously…View ↗
Competes with Becton, Dickinson and, Thermo Fisher Scientific, and Bio-Rad Laboratories
10-K for FY2022, filed Mar 2, 2023We face significant competition in the life sciences technology market. We currently compete with many established technology companies in…View ↗
Loading...
